Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Celldex Therapeutics, Inc. Director's Dealing 2021

Aug 13, 2021

31801_dirs_2021-08-13_7cab2275-1b4a-46e3-9407-19d0388410ec.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-08-11

Reporting Person: Jimenez Freddy A. (SVP & General Counsel)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-11 Common Stock P 430 $46.28 Acquired 430 Direct